Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Recruited Monocyte-Derived Macrophages Drive T Cell Inflammation in Immune Checkpoint Inhibitor-Mediated Pneumonitis. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41571-022-00600-w
10.1038/s41571-022-00600-w · External reference
10.1038/s41572-020-0160-6
10.1038/s41572-020-0160-6 · External reference
10.1038/s41571-021-00597-8
10.1038/s41571-021-00597-8 · External reference
10.1038/s41573-021-00259-5
10.1038/s41573-021-00259-5 · External reference
Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis
10.1001/jamaoncol.2018.3923 · 2018 · External reference
10.1038/s41571-019-0218-0
10.1038/s41571-019-0218-0 · External reference
Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors
10.1016/j.jtho.2018.08.2035 · 2018 · External reference
Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy
10.1016/j.jtho.2018.11.016 · 2019 · External reference
Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: Analysis of six clinical trials
10.1200/jco.24.00191 · 2024 · External reference
Pulmonary toxicity of immune checkpoint immunotherapy
10.1172/jci170503 · 2024 · External reference
Targeting molecular pathways to control immune checkpoint inhibitor toxicities
10.1016/j.it.2024.11.014 · 2025 · External reference
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
10.1172/jci128654 · 2019 · External reference
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance
10.1186/s40425-019-0645-6 · 2019 · External reference
10.1016/j.immuni.2022.08.010
10.1016/j.immuni.2022.08.010 · External reference
10.1016/j.molmed.2016.02.004
10.1016/j.molmed.2016.02.004 · External reference
10.1016/j.immuni.2020.05.014
10.1016/j.immuni.2020.05.014 · External reference
10.1164/rccm.202004-0991oc
10.1164/rccm.202004-0991oc · External reference
10.1164/rccm.202401-0078oc
10.1164/rccm.202401-0078oc · External reference
10.1016/j.cell.2020.08.001
10.1016/j.cell.2020.08.001 · External reference
Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis
10.1038/s41388-023-02805-4 · 2023 · External reference
Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
10.1136/jitc-2022-005323 · 2022 · External reference
10.1146/annurev-immunol-032713-120145
10.1146/annurev-immunol-032713-120145 · External reference
10.1111/imr.12757
10.1111/imr.12757 · External reference
10.1164/rccm.202004-1132oc
10.1164/rccm.202004-1132oc · External reference
10.1016/j.ymthe.2024.01.022
10.1016/j.ymthe.2024.01.022 · External reference
10.1158/0008-5472.can-16-0194
10.1158/0008-5472.can-16-0194 · External reference
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
10.1136/jitc-2020-001687 · 2020 · External reference
10.1016/j.cell.2019.05.031
10.1016/j.cell.2019.05.031 · External reference
10.1038/s41592-019-0619-0
10.1038/s41592-019-0619-0 · External reference
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
10.1136/jitc-2021-002435 · 2021 · External reference
Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
10.1200/jco.2016.68.2005 · 2017 · External reference
10.1016/j.immuni.2015.08.010
10.1016/j.immuni.2015.08.010 · External reference
10.1016/j.cell.2021.04.048
10.1016/j.cell.2021.04.048 · External reference
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data
2021 · External reference
10.1186/1471-2105-14-7
10.1186/1471-2105-14-7 · External reference
10.1038/s41587-019-0068-4
10.1038/s41587-019-0068-4 · External reference
10.1038/s41596-020-0336-2
10.1038/s41596-020-0336-2 · External reference
10.1038/s41596-024-01045-4
10.1038/s41596-024-01045-4 · External reference
10.1165/rcmb.2009-0210st
10.1165/rcmb.2009-0210st · External reference
Rapid clearance of heavy chain-modified hyaluronan during resolving acute lung injury
10.1186/s12931-018-0812-1 · 2018 · External reference
10.1165/rcmb.2013-0086ma
10.1165/rcmb.2013-0086ma · External reference
Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis
10.1016/j.celrep.2022.111797 · 2022 · External reference
10.1038/s41598-017-17204-5
10.1038/s41598-017-17204-5 · External reference
10.1111/cas.15724
10.1111/cas.15724 · External reference
Exercise suppresses mouse systemic AApoAII amyloidosis through enhancement of the p38 MAPK signaling pathway
10.1242/dmm.049327 · 2022 · External reference
10.1038/ni1428
10.1038/ni1428 · External reference
Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development
10.1038/s41467-024-46457-8 · 2024 · External reference
10.1016/j.it.2019.08.003
10.1016/j.it.2019.08.003 · External reference
10.1016/j.semcancer.2019.01.006
10.1016/j.semcancer.2019.01.006 · External reference
Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNgamma axis
10.1038/s41467-023-41798-2 · 2023 · External reference
Non-invasive detection of immunotherapy-induced adverse events
10.1158/1078-0432.ccr-20-4641 · 2021 · External reference
10.1016/j.it.2023.10.005
10.1016/j.it.2023.10.005 · External reference
10.1038/s41590-023-01468-3
10.1038/s41590-023-01468-3 · External reference
Macrophages in cardiovascular diseases: Molecular mechanisms and therapeutic targets
10.1038/s41392-024-01840-1 · 2024 · External reference
CCR2 signaling restricts SARS-CoV-2 infection
10.1128/mbio.02749-21 · 2021 · External reference
10.1038/s41577-020-0331-4
10.1038/s41577-020-0331-4 · External reference
IFN-gamma and LPS induce synergistic expression of CCL2 in monocytic cells via H3K27 acetylation
10.2147/jir.s368352 · 2022 · External reference
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
10.1172/jci.insight.142513 · 2021 · External reference
10.1073/pnas.95.9.5205
10.1073/pnas.95.9.5205 · External reference
Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1
10.1111/j.1476-5381.2009.00143.x · 2009 · External reference
10.1016/j.smim.2009.05.011
10.1016/j.smim.2009.05.011 · External reference
10.1007/s00018-019-03255-6
10.1007/s00018-019-03255-6 · External reference
Targeting interferon-gamma in hyperinflammation: Opportunities and challenges
10.1038/s41584-021-00694-z · 2021 · External reference
The IFN-gamma-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment
10.1002/eji.202250281 · 2024 · External reference
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
10.1136/jitc-2021-003594 · 2021 · External reference
10.1161/circulationaha.121.056730
10.1161/circulationaha.121.056730 · External reference
10.1161/circresaha.124.325652
10.1161/circresaha.124.325652 · External reference
Immune dysregulation in cancer patients developing immune-related adverse events
10.1038/s41416-018-0155-1 · 2019 · External reference
The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
10.1016/j.addr.2024.115318 · 2024 · External reference
10.1093/eurheartj/ehac094
10.1093/eurheartj/ehac094 · External reference
Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible treatments: All options on the table
10.1016/j.intimp.2022.109325 · 2022 · External reference
10.1038/s41577-022-00737-w
10.1038/s41577-022-00737-w · External reference
10.1016/j.it.2020.12.001
10.1016/j.it.2020.12.001 · External reference
10.1084/jem.20021897
10.1084/jem.20021897 · External reference
Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion
10.1186/1476-4598-11-3 · 2012 · External reference
Non-immune targeting of CXCR3 compromises mitochondrial function and suppresses tumor growth in glioblastoma
10.1038/s41420-025-02449-1 · 2025 · External reference
Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer
10.1158/0008-5472.can-06-0709 · 2006 · External reference
CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
10.1158/1535-7163.mct-08-0485 · 2009 · External reference
10.1038/sj.onc.1210267
10.1038/sj.onc.1210267 · External reference
10.1016/j.immuni.2012.08.016
10.1016/j.immuni.2012.08.016 · External reference
CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells
10.1016/j.immuni.2015.02.009 · 2015 · External reference
10.1111/bjd.14416
10.1111/bjd.14416 · External reference
A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment
10.1007/s00018-023-04715-w · 2023 · External reference
Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: Relevance for arthritis
10.1186/s13075-017-1353-6 · 2017 · External reference
Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis
10.1161/circulationaha.122.062551 · 2024 · External reference
CXCR3 antagonist AMG487 suppresses rheumatoid arthritis pathogenesis and progression by shifting the Th17/Treg cell balance
10.1016/j.cellsig.2019.109395 · 2019 · External reference
CXCR3 antagonist AMG487 inhibits glucocorticoid-induced tumor necrosis factor-receptor-related protein and inflammatory mediators in CD45 expressing cells in collagen-induced arthritis mouse model
10.1016/j.intimp.2020.106494 · 2020 · External reference
CXC chemokine receptor 3 antagonist AMG487 shows potent anti-arthritic effects on collagen-induced arthritis by modifying B cell inflammatory profile
10.1016/j.imlet.2020.06.014 · 2020 · External reference
10.1016/j.tem.2024.04.009
10.1016/j.tem.2024.04.009 · External reference
Systems level identification of a matrisome-associated macrophage polarisation state in multi-organ fibrosis
10.7554/elife.85530 · 2023 · External reference
